GLIOTRAIN SIGNED
Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0GLIOTRAIN project word cloud
Explore the words cloud of the GLIOTRAIN project. It provides you a very rough idea of what is the project "GLIOTRAIN" about.
Project "GLIOTRAIN" data sheet
The following table provides information about the project.
| Coordinator |
ROYAL COLLEGE OF SURGEONS IN IRELAND
Organization address contact info |
| Coordinator Country | Ireland [IE] |
| Project website | https://www.gliotrain.eu/ |
| Total cost | 3˙836˙772 € |
| EC max contribution | 3˙836˙772 € (100%) |
| Programme |
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers) |
| Code Call | H2020-MSCA-ITN-2017 |
| Funding Scheme | MSCA-ITN-ETN |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-09-01 to 2021-08-31 |
Partnership
Take a look of project's partnership.
Map
Project objective
Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patients dying within two years. New treatment options and effective precision medicine therapies are urgently required. This can only be achieved by focused multi-sectoral industry-academia collaborations in newly emerging, innovative research disciplines. GLIOTRAIN will exploit the intractability of GBM to address European applied biomedical research training needs. The ETN, which comprises 9 beneficiaries and 14 partner organisations from 8 countries, will train 15 innovative, creative and entrepreneurial ESRs. The research objective of GLIOTRAIN is to identify novel therapeutic strategies for application in GBM, while implementing state of the art next generation sequencing, systems medicine and integrative multi-omics to unravel disease resistance mechanisms. Research activities incorporate applied systems medicine, integrative multi-omics leveraging state of the art platform technologies, and translational cancer biology implementing the latest clinically relevant models. The consortium brings together leading European and international academics, clinicians, private sector and not-for-profit partners across GBM fields of tumour biology, multi-omics, drug development, clinical research, bioinformatics, computational modelling and systems biology. Thus, GLIOTRAIN will address currently unmet translational research and clinical needs in the GBM field by interrogating innovative therapeutic strategies and improving the mechanistic understanding of disease resistance. The GLIOTRAIN ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans translational research, medicine and computational biology, and that can navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.
Deliverables
| Dissemination and public engagement Report 1 | Documents, reports | 2020-01-14 15:07:41 |
| GLIOTRAIN Web presence | Websites, patent fillings, videos etc. | 2020-01-14 15:09:36 |
| Dissemination and public engagement Report 2 | Documents, reports | 2020-01-14 15:06:43 |
Take a look to the deliverables list in detail: detailed list of GLIOTRAIN deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2018 |
Annika Hantusch; Kushal K. Das; Ana J. GarcÃa-Sáez; Thomas Brunner; Markus Rehm Bax retrotranslocation potentiates Bcl-xL’s antiapoptotic activity and is essential for switch-like transitions between MOMP competency and resistance published pages: 430, ISSN: 2041-4889, DOI: 10.1038/s41419-018-0464-6 |
Cell Death & Disease 9 (4) | 2019-10-15 |
| 2019 |
Ian S. Miller, Liam P. Shiels, Emer Conroy, Kate Connor, Patrick Dicker, William M. Gallagher, Norma O’ Donovan, Robert S. Kerbel, John Crown, Annette T. Byrne Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents published pages: 9204, ISSN: 2045-2322, DOI: 10.1038/s41598-019-45444-0 |
Scientific Reports 9/1 | 2019-10-15 |
| 2018 |
Frank A. Lincoln, Dirke Imig, Chiara Boccellato, Viktorija Juric, Janis Noonan, Roland E. Kontermann, Frank Allgöwer, Brona M. Murphy, Markus Rehm Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism published pages: 1112, ISSN: 2041-4889, DOI: 10.1038/s41419-018-1160-2 |
Cell Death & Disease 9/11 | 2019-10-15 |
| 2019 |
Bo Lou, Kate Connor, Kieron Sweeney, Ian S. Miller, Alice O’Farrell, Eduardo Ruiz-Hernandez, David M. Murray, Garry P. Duffy, Alan Wolfe, Enrico Mastrobattista, Annette T. Byrne, Wim E. Hennink RGD-decorated cholesterol stabilized polyplexes for targeted siRNA delivery to glioblastoma cells published pages: 679-693, ISSN: 2190-393X, DOI: 10.1007/s13346-019-00637-y |
Drug Delivery and Translational Research 9/3 | 2019-10-15 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLIOTRAIN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GLIOTRAIN" are provided by the European Opendata Portal: CORDIS opendata.